Aflac Reports Q4 2025 Earnings with Mixed Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy AFL?
Source: seekingalpha
Aflac Inc (AFL) shares rose by 3.00% and reached a 52-week high amid a challenging market environment, as both the Nasdaq-100 and S&P 500 indices experienced declines of 1.15% and 1.00%, respectively.
The company's Q4 2025 earnings report revealed a revenue decline of 9.9% year-over-year, totaling $4.9 billion, and a net earnings drop of 27.5% to $1.4 billion. Despite these challenges, Aflac Japan reported a significant 15.7% increase in new annualized premium sales, driven by the cancer insurance product Miraito, indicating potential for future growth. Additionally, Aflac announced a 5.2% increase in its dividend and a substantial share repurchase program, reflecting a commitment to shareholder value.
These mixed results suggest that while Aflac faces competitive pressures, its strategic focus on product innovation and capital management may bolster investor confidence in the long term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFL
Wall Street analysts forecast AFL stock price to fall
11 Analyst Rating
3 Buy
5 Hold
3 Sell
Hold
Current: 114.670
Low
100.00
Averages
110.90
High
125.00
Current: 114.670
Low
100.00
Averages
110.90
High
125.00
About AFL
Aflac Incorporated provides financial protection to policyholders and customers through its subsidiaries in the United States and Japan. The Company’s principal business is supplemental health and life insurance products. The Company’s segments include Aflac Japan, which includes Aflac Life Insurance Japan (ALIJ), and Aflac U.S., which includes American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS). The Aflac Japan segment is the insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force. The Company designs its United States insurance products to provide supplemental coverage for people who already have major medical or primary insurance coverage, as Aflac U.S. insurance policies pay benefits regardless of other insurance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aflac Named Among 15 Best Cheap Dividend Stocks
- Target Price Adjustment: UBS has lowered Aflac's (AFL) price target from $116 to $114 while maintaining a Neutral rating, indicating limited profitability potential amid economic uncertainty and cyclicality.
- Earnings Guidance: During the Q4 2025 earnings call, Aflac executives stated that most of the 2026 guidance remains intact, with underlying earned premiums in Japan expected to decline by 1% to 2%, which could pressure overall revenue.
- US Business Outlook: Aflac anticipates net earned premium growth to remain at the lower end of the 3% to 6% range, with a projected benefit ratio between 48% and 52%, suggesting challenges as the company expands its newer business lines.
- Expense Ratio Forecast: The company expects the expense ratio in the U.S. to range from 36% to 39%, indicating ongoing efforts to optimize its business structure despite economic headwinds to support future growth.
See More
Concerns Over Private Credit Persist, Cautions Insurance Company Investment Strategist
- Market Reactions: The stock market is experiencing a surge due to a cease-fire in Iran, leading to optimism among investors.
- Ongoing Concerns: Despite the positive market response, investors remain wary of underlying issues in the private credit sector.
See More
Aflac to Release Q1 2026 Financial Results on April 29
- Earnings Release Schedule: Aflac plans to release its Q1 2026 financial results after market close on April 29, 2026, providing quarterly earnings and financial supplement materials to ensure timely access to critical information for investors.
- Webcast Conference Call: The company will host a conference call on April 30, 2026, at 8:00 a.m. ET, where CEO Daniel P. Amos and other executives will discuss quarterly results, enhancing transparency and investor confidence.
- Future Earnings Forecast: Aflac has also announced future earnings release dates, with Q2 2026 results set for August 6 and Q3 2026 results on November 4, allowing investors to prepare in advance for upcoming financial disclosures.
- Company Background: As a Fortune 500 company, Aflac has provided financial protection to millions of policyholders for over seven decades, leading the supplemental health insurance market in the U.S. and demonstrating strong corporate responsibility and influence in the insurance industry.
See More
Aflac Partners with Japan Post Insurance for Reinsurance Agreement
- Reinsurance Agreement: Aflac Re Bermuda Ltd. has entered into a reinsurance agreement with Japan Post Insurance Co., Ltd. involving a block of whole life annuities through coinsurance, marking Aflac's first transaction with an external partner, which is expected to enhance the company's competitive position in the market.
- Strategic Partnership Strengthened: This transaction not only represents the first collaboration between Aflac Re and Japan Post Insurance but also further solidifies their strategic partnership aimed at creating shared value for policyholders and shareholders, thereby improving overall business performance.
- Risk Management Optimization: Aflac Re plans to leverage its expertise to support other Japanese life insurers in reducing risk, enhancing capital management, and expanding new business opportunities, which will contribute to the stability of the entire industry.
- Industry Leadership Reinforced: Aflac's market leadership in both the U.S. and Japan is further solidified, as it remains the largest provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan, enhancing the company's reputation and market share.
See More
Aflac Re Partners with Japan Post Insurance for Coinsurance Agreement
- Reinsurance Milestone: Aflac Re Bermuda Ltd. has entered into a coinsurance agreement with Japan Post Insurance, marking Aflac's first transaction with an external partner, which is expected to enhance the strategic partnership and create shared value for policyholders and shareholders.
- Policy Management Continuity: Japan Post Insurance will continue to service and administer the whole life annuity policies, ensuring continuity in customer service while enhancing Aflac's competitive position in the Japanese market.
- Risk Management Optimization: Aflac Re plans to leverage its expertise to support other Japanese life insurers in reducing risk and enhancing capital management, which will help expand new business opportunities and further solidify Aflac's leadership in the industry.
- Long-term Strategic Commitment: This transaction not only deepens the relationship between Aflac Re and Japan Post Insurance but also reflects Aflac's long-term investment commitment to the Japanese market, aiming to collaboratively address market challenges and seize growth opportunities.
See More
Aflac Re Bermuda Ltd. Announces Reinsurance Agreement with Japan Post Insurance
- Reinsurance Milestone: Aflac Re Bermuda Ltd. has reached a reinsurance agreement with Japan Post Insurance involving a block of whole life annuities through coinsurance, marking Aflac's first transaction with an external partner, which is expected to enhance the company's market position and financial stability.
- Strategic Partnership Deepening: This transaction not only deepens the collaboration between Aflac Re and Japan Post Insurance but also aims to create shared value for both policyholders and shareholders, further solidifying their strategic partnership.
- Risk Management Support: Aflac Re plans to leverage its expertise to provide similar support to other Japanese life insurers, helping them reduce risk, enhance capital management, and expand new business opportunities, thereby strengthening the overall industry stability.
- Industry Leadership Reinforced: Aflac's market leadership in the U.S. and Japan is further reinforced, as the company remains the largest provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan, with this transaction expected to enhance its reputation and market share.
See More
Aflac Named Among 15 Best Cheap Dividend Stocks
- Target Price Adjustment: UBS has lowered Aflac's (AFL) price target from $116 to $114 while maintaining a Neutral rating, indicating limited profitability potential amid economic uncertainty and cyclicality.
- Earnings Guidance: During the Q4 2025 earnings call, Aflac executives stated that most of the 2026 guidance remains intact, with underlying earned premiums in Japan expected to decline by 1% to 2%, which could pressure overall revenue.
- US Business Outlook: Aflac anticipates net earned premium growth to remain at the lower end of the 3% to 6% range, with a projected benefit ratio between 48% and 52%, suggesting challenges as the company expands its newer business lines.
- Expense Ratio Forecast: The company expects the expense ratio in the U.S. to range from 36% to 39%, indicating ongoing efforts to optimize its business structure despite economic headwinds to support future growth.
See More
Concerns Over Private Credit Persist, Cautions Insurance Company Investment Strategist
- Market Reactions: The stock market is experiencing a surge due to a cease-fire in Iran, leading to optimism among investors.
- Ongoing Concerns: Despite the positive market response, investors remain wary of underlying issues in the private credit sector.
See More
Aflac to Release Q1 2026 Financial Results on April 29
- Earnings Release Schedule: Aflac plans to release its Q1 2026 financial results after market close on April 29, 2026, providing quarterly earnings and financial supplement materials to ensure timely access to critical information for investors.
- Webcast Conference Call: The company will host a conference call on April 30, 2026, at 8:00 a.m. ET, where CEO Daniel P. Amos and other executives will discuss quarterly results, enhancing transparency and investor confidence.
- Future Earnings Forecast: Aflac has also announced future earnings release dates, with Q2 2026 results set for August 6 and Q3 2026 results on November 4, allowing investors to prepare in advance for upcoming financial disclosures.
- Company Background: As a Fortune 500 company, Aflac has provided financial protection to millions of policyholders for over seven decades, leading the supplemental health insurance market in the U.S. and demonstrating strong corporate responsibility and influence in the insurance industry.
See More
Aflac Partners with Japan Post Insurance for Reinsurance Agreement
- Reinsurance Agreement: Aflac Re Bermuda Ltd. has entered into a reinsurance agreement with Japan Post Insurance Co., Ltd. involving a block of whole life annuities through coinsurance, marking Aflac's first transaction with an external partner, which is expected to enhance the company's competitive position in the market.
- Strategic Partnership Strengthened: This transaction not only represents the first collaboration between Aflac Re and Japan Post Insurance but also further solidifies their strategic partnership aimed at creating shared value for policyholders and shareholders, thereby improving overall business performance.
- Risk Management Optimization: Aflac Re plans to leverage its expertise to support other Japanese life insurers in reducing risk, enhancing capital management, and expanding new business opportunities, which will contribute to the stability of the entire industry.
- Industry Leadership Reinforced: Aflac's market leadership in both the U.S. and Japan is further solidified, as it remains the largest provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan, enhancing the company's reputation and market share.
See More
Aflac Re Partners with Japan Post Insurance for Coinsurance Agreement
- Reinsurance Milestone: Aflac Re Bermuda Ltd. has entered into a coinsurance agreement with Japan Post Insurance, marking Aflac's first transaction with an external partner, which is expected to enhance the strategic partnership and create shared value for policyholders and shareholders.
- Policy Management Continuity: Japan Post Insurance will continue to service and administer the whole life annuity policies, ensuring continuity in customer service while enhancing Aflac's competitive position in the Japanese market.
- Risk Management Optimization: Aflac Re plans to leverage its expertise to support other Japanese life insurers in reducing risk and enhancing capital management, which will help expand new business opportunities and further solidify Aflac's leadership in the industry.
- Long-term Strategic Commitment: This transaction not only deepens the relationship between Aflac Re and Japan Post Insurance but also reflects Aflac's long-term investment commitment to the Japanese market, aiming to collaboratively address market challenges and seize growth opportunities.
See More
Aflac Re Bermuda Ltd. Announces Reinsurance Agreement with Japan Post Insurance
- Reinsurance Milestone: Aflac Re Bermuda Ltd. has reached a reinsurance agreement with Japan Post Insurance involving a block of whole life annuities through coinsurance, marking Aflac's first transaction with an external partner, which is expected to enhance the company's market position and financial stability.
- Strategic Partnership Deepening: This transaction not only deepens the collaboration between Aflac Re and Japan Post Insurance but also aims to create shared value for both policyholders and shareholders, further solidifying their strategic partnership.
- Risk Management Support: Aflac Re plans to leverage its expertise to provide similar support to other Japanese life insurers, helping them reduce risk, enhance capital management, and expand new business opportunities, thereby strengthening the overall industry stability.
- Industry Leadership Reinforced: Aflac's market leadership in the U.S. and Japan is further reinforced, as the company remains the largest provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan, with this transaction expected to enhance its reputation and market share.
See More
